Results 181 to 190 of about 3,473,423 (297)

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Mie Voids for Single-Molecule Fluorescence Enhancement in Wavelength-Scale Detection Volumes. [PDF]

Sensors (Basel)
Kuznetsov I, Shuklin F, Ryabkov E, Barulina E, Petukhov A, Baranov DG, Chernov A, Barulin A.   +7 more
europepmc   +1 more source

Induction of MHC Class I Presentation of Exogenous Antigen by Dendritic Cells Is Controlled by CD4+ T Cells Engaging Class II Molecules in Cholesterol-Rich Domains [PDF]

, 2002
Patrick Machy, Karine Serre, Marjorie Baillet, Lee Leserman   +3 more
openalex   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

What Does It Take for an Organic Closed Shell Molecule to Become Magnetic? [PDF]

J Phys Chem Lett
Fransson J.
europepmc   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide

ACS Omega, 2022
Jingyao Wang, Mark R. Berglund, Timothy Braden, Matthew C. Embry, Martin D. Johnson, Stephen R. Groskreutz, Fareed Bhasha Sayyed, Sergey Vladimirovich Tsukanov, Timothy D. White, Ankur Jalan, Kevin D. Seibert, Michael E. Kopach   +11 more
doaj   +1 more source

Nanobody-drug conjugates for targeting specific GPCR pairs. [PDF]

PLoS Biol
Huang X, Roth BL.
europepmc   +1 more source

Galectin-9: An anticancer molecule for gallbladder carcinoma

, 2016
Tomoko Tadokoro, Asahiro Morishita, Shintaro Fujihara, Hisakazu Iwama, Toshiro Niki, Koji Fujita, Emiko Akashi, Shima Mimura, Kyoko Oura, Teppei Sakamoto, Takako Nomura, Joji Tani, Hisaaki Miyoshi, Hirohito Yoneyama, Takashi Himoto, Mitsuomi Hirashima, Tsutomu Masaki   +16 more
openalex   +2 more sources

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source